Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory

被引:49
|
作者
Gning, Ibrahima [1 ]
Trask, Peter C. [3 ]
Mendoza, Tito R. [1 ]
Harle, Margaret T. [1 ]
Gutierrez, Karla A. [1 ]
Kitaka, Sheila A. [2 ]
Sherman, Steven I. [2 ]
Cleeland, Charles S. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
[3] Pfizer Inc, Global Outcomes Res, New London, CT USA
关键词
Symptoms; Assessment; Validation; Thyroid cancer; Module of the M. D. Anderson Symptom Inventory; QUALITY-OF-LIFE; INSTRUMENTS; WITHDRAWAL; THYROXINE; VERSION;
D O I
10.1159/000178809
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The M. D. Anderson Symptom Inventory (MDASI) and its modules measure common symptoms related to cancer and its treatment. We report the development and initial validation of the MDASI-Thyroid Cancer module (MDASI-THY). Methods: A list of thyroid-cancer-specific symptoms was generated through focus groups and interviews with thyroid cancer patients, clinicians and researchers. These MDASI-THY items were added to the original MDASI and administered to 60 patients with thyroid cancer. Symptom prevalence and severity were evaluated, along with the reliability and content, construct and known-group validity of the MDASI-THY. Results: Cognitive debriefing performed on a subset of patients indicated that the MDASI-THY items were clear, concise, relevant and easy to understand. Fatigue, drowsiness, sleep disturbance, distress and difficulty remembering were the 5 most prevalent and severe symptoms. Twenty-eight percent of patients had moderate to severe fatigue (>= 5 on a 0-10 scale). Average severity was 1.28 and 1.29 for the symptom and interference subscales, respectively. MDASI-THY symptoms were severer for patients with poorer performance status. Cronbach alpha-values were 0.76, 0.85 and 0.92 for the thyroid-specific symptom items, core symptom subscale and interference subscale, respectively. Conclusions: This study demonstrates preliminary evidence for the validity and reliability of the MDASI-THY. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [41] The reliability and validity of the M. D. Anderson Symptom Inventory (MDASI-HN) as a measure of symptom burden in the head and neck cancer (HNC) patient population
    Rosenthal, DI
    Chambers, MS
    Mendoza, TR
    Asper, JA
    Kies, MS
    Weber, RS
    Garden, AS
    Ang, KK
    Wang, XS
    Cleeland, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 753S - 753S
  • [42] Chinese version of the M.D. Anderson Symptom Inventory - Validation and application of symptom measurement in cancer patients
    Wang, XS
    Wang, Y
    Guo, H
    Mendoza, TR
    Hao, XS
    Cleeland, CS
    CANCER, 2004, 101 (08) : 1890 - 1901
  • [43] The M. D. Anderson Memorial Library
    McGaw, Howard F.
    COLLEGE & RESEARCH LIBRARIES, 1953, 14 (02): : 130 - 135
  • [44] Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
    Cabanillas, Maria E.
    Waguespack, Steven G.
    Bronstein, Yulia
    Williams, Michelle D.
    Feng, Lei
    Hernandez, Mike
    Lopez, Adriana
    Sherman, Steven I.
    Busaidy, Naifa L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2588 - 2595
  • [45] Translation and validation of MD Anderson Symptom Inventory-Thyroid Cancer module in Chinese thyroid cancer patients: a cross-sectional and methodological study
    Hu, Zi-yi
    Gou, Ju-xiang
    Cai, Ming
    Zhang, Yue-er
    BMC CANCER, 2022, 22 (01)
  • [46] Cancer-related symptom assessment in Russia: Validation and utility of the Russian M.D. Anderson symptom inventory
    Ivanova, MO
    Ionova, TI
    Kalyadina, SA
    Uspenskaya, OS
    Kishtovich, AV
    Guo, H
    Mendoza, TR
    Novik, A
    Cleeland, CS
    Wang, XS
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 30 (05) : 443 - 453
  • [47] Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting
    Kamal, Mona
    Navai, Neema
    Bree, Kelly K.
    Williams, Loretta A.
    Cleeland, Charles S.
    Shen, Shu-En
    Wang, Xin Shelley
    CANCERS, 2022, 14 (16)
  • [48] Linguistic Validation of the Turkish Version of the MD Anderson Symptom Inventory - Head and Neck Cancer Module
    Gunn, G. Brandon
    Atalar, Banu
    Mendoza, Tito R.
    Cleeland, Charles S.
    Selek, Ugur
    Ozyar, Enis
    Rosenthal, David I.
    BALKAN MEDICAL JOURNAL, 2016, 33 (03) : 339 - 343
  • [49] Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience
    Tsimberidou, Apostolia Maria
    Vaklavas, Christos
    Wen, Sijin
    Hong, David
    Wheler, Jennifer
    Ng, Chaan
    Naing, Aung
    Tse, Susan
    Busaidy, Naifa
    Markman, Maurie
    Sherman, Steven I.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (11): : 4423 - 4432
  • [50] THE M. D. ANDERSON SYMPTOM INVENTORY-HEAD AND NECK MODULE, A PATIENT-REPORTED OUTCOME INSTRUMENT, ACCURATELY PREDICTS THE SEVERITY OF RADIATION-INDUCED MUCOSITIS
    Rosenthal, David I.
    Mendoza, Tito R.
    Chambers, Mark S.
    Burkerr, V. Shannon
    Garden, Adam S.
    Hessell, Amy C.
    Lewin, Jan S.
    Ang, K. Kian
    Kies, Merrill S.
    Gning, Brahima
    Wang, Xin S.
    Cleeland, Charles S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (05): : 1355 - 1361